Phase 4Not yet recruiting
A Phase IV, Two-part, Open-label Study Assessing the Pharmacokinetics, Safety and Pharmacodynamics of Spironolactone Oral Suspension in Pediatric Patients
A Phase IV, Two-part, Open-label Study Assessing the Pharmacokinetics, Safety and Pharmacodynamics of Single and Multiple Doses of Spironolactone Oral Suspension in Pediatric Patients With Edema Due to Heart Failure or Cirrhosis
- Sponsor
- CMP Development, LLC (Industry)
- Enrollment
- 96 planned
- Conditions
- Edema Due to Heart Failure or Cirrhosis
- Interventions
- Spironolactone Oral Suspension
- Ages
- children
- Registry
- NCT06021860
Full record on ClinicalTrials.gov
From the registry
This is a 2-part, 2 periods per part, open-label study with spironolactone oral suspension in pediatric patients with edema due to HF or hepatic cirrhosis. Both study parts will evaluate the safety, PK and PD of multiple doses of spironolactone in patients aged from birth to ≤17 years of age.
Primary outcomes
- Part 1: Absorption rate constant (Ka) of spironolactone (time^-1) in the multiple-dose period
- Part 2: Absorption rate constant (Ka) of spironolactone (time^-1) in the multiple-dose period
- Part 1: Total clearance from plasma after oral administration (CL/F) of spironolactone in the multiple-dose period
- Part 2: Total clearance from plasma after oral administration (CL/F) of spironolactone in the multiple-dose period
History
Study completion expected
Primary completion expected
Expected to start
Now not yet recruiting
, from Status unknown to Not yet recruiting
Completion moved to Jun 2028
, from Mar 2025 to Jun 2028
Last registry update
Registered